lilly tirzepatide https://investor.lilly.com/news-releases/news-release-details/zepbound- tirzepatide-most-prescribed-weight-management “Eli and Company (NYSE: LLY) today announced the U.S. Food and Drug Administration (FDA) approved a label expansion for Zepbound A new weight loss drug

Standard contraceptive precautions apply

Research suggests that women are more sensitive to pain and have lower thresholds to experimental pain than men, likely due to differences in the immune system and hormonal influences

Common side effects reported in trials include: Nausea (the most frequently reported adverse effect) Vomiting Diarrhoea Constipation Decreased appetite Abdominal discomfort or bloating These effects are generally dose-dependent and tend to improve over time as the body adapts to the medication

Molecules 23(4):745

Anavar was one of the first steroids used specifically for physique enhancement rather than pure mass building

GLP-1 receptor agonists have been approved to treat diabetes since 2005 and obesity since 2014